Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00

Zevra Therapeutics (NASDAQ:ZVRA) had its target price hoisted by analysts at Canaccord Genuity Group from $23.00 to $25.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 212.11% from the company’s current price.

ZVRA has been the subject of a number of other reports. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Finally, Guggenheim increased their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $22.14.

Zevra Therapeutics Stock Up 1.1 %

NASDAQ ZVRA traded up $0.09 on Thursday, hitting $8.01. 338,270 shares of the stock traded hands, compared to its average volume of 412,217. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a 50-day moving average of $7.95 and a 200 day moving average of $8.14. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a market capitalization of $427.54 million, a P/E ratio of -4.06 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The firm had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. As a group, analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares in the company, valued at $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock worth $674,176 in the last ninety days. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Woodline Partners LP boosted its stake in Zevra Therapeutics by 2.2% during the fourth quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock worth $34,524,000 after buying an additional 90,940 shares in the last quarter. Velan Capital Investment Management LP increased its stake in Zevra Therapeutics by 50.0% in the fourth quarter. Velan Capital Investment Management LP now owns 300,000 shares of the company’s stock valued at $2,502,000 after acquiring an additional 100,000 shares during the period. Squarepoint Ops LLC raised its position in Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock worth $138,000 after purchasing an additional 4,384 shares in the last quarter. ProShare Advisors LLC bought a new position in Zevra Therapeutics during the fourth quarter worth about $145,000. Finally, Millennium Management LLC boosted its holdings in Zevra Therapeutics by 138.2% during the fourth quarter. Millennium Management LLC now owns 233,132 shares of the company’s stock valued at $1,944,000 after purchasing an additional 135,246 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.